Gene expression markers in the zebrafish embryo reflect a hepatotoxic response in animal models and humans

Toxicology Letters

Volumn 230, Issue 1, 2014, Pages 48-56

  Driessen, Marja ^a,b   Kienhuis, Anne S ^a   Vitins, Alexa P ^a,c   Pennings, Jeroen L A ^a   Pronk, Tessa E ^a,c   Brandhof, Evert Jan van den ^a   Roodbergen, Marianne ^a,b   Water, Bob van de ^b   Ven, Leo T M van der ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYP19A1B PROTEIN; CYP24A1 PROTEIN; CYP2AA3 PROTEIN; CYP2K19 PROTEIN; CYP4V7 PROTEIN; CYTOCHROME P450; PKLR PROTEIN; PROTEIN; SLC2A9L2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LIVER CELL; LIVER NECROSIS; LIVER TOXICITY; MALE; MORPHOLOGICAL TRAIT; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; STEATOSIS; UPREGULATION; XENOBIOTIC METABOLISM; ZEBRA FISH;

ANIMALS; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE REGULATORY NETWORKS; GENETIC MARKERS; HUMANS; LIVER; MODELS, ANIMAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICITY TESTS; ZEBRAFISH;

EID: 84906049810     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.06.844     Document Type: Article

References (38)

1. Alderton W.I., Berghmans S., Butler P., Chassaing H., Fleming A., Golder Z., Richards F., Gardner I. Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae. Xenobiotica 2010, 40:547-557.
2. Amali A.A., Rekha R.D., Lin C.J.-F., Wang W.-L., Gong H.-Y., Her G.-M., Wu J.-L. Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J. Biomed. Sci. 2006, 13:225-232.
3. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008, 60:311-357.
4. Ansede J.H., Smith W.R., Perry C.H., St Claire R.L., Brouwer K.R. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab. Dispos 2010, 38:276-280.
5. Blomme E.A.G., Yang Y., Waring J.F. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 2009, 186:22-31.
6. Bohan A., Boyer J.L. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin. Liver Dis. 2002, 22:123-136.
7. Boorsma A., Foat B.C., Vis D., Klis F., Bussemaker H.J. T-profiler: scoring the activity of predefined groups of genes using gene expression data. Nucleic Acids Res. 2005, 33:W592-W595.
8. Bradford Y., Conlin T., Dunn N., Fashena D., Frazer K., Howe D.G., Knight J., Mani P., Martin R., Moxon S.A.T., Paddock H., Pich C., Ramachandran S., Ruef B.J., Ruzicka L., Bauer Schaper H., Schaper K., Shao X., Singer A., Sprague J., Sprunger B., Van Slyke C., Westerfield M. ZFIN: enhancements and updates to the zebrafish model organism database. Nucleic Acids Res. 2011, 39:D822-D829.
9. Chang C., Hu M., Zhu Z., Lo L.J., Chen J., Peng J. liver-enriched gene 1a and 1b encode novel secretory proteins essential for normal liver development in zebrafish. PLoS ONE 2011, 6:e22910.
10. Dai M., Wang P., Boyd A.D., Kostov G., Athey B., Jones E.G., Bunney W.E., Myers R.M., Speed T.P., Akil H., Watson S.J., Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33(20):e175.
11. de Jong M., Rauwerda H., Bruning O., Verkooijen J., Spaink H.P., Breit T.M. RNA isolation method for single embryo transcriptome analysis in zebrafish. BMC Res. Notes 2010, 3:73.
12. DeLeve L.D., Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol. Ther. 1991, 52:287-305.
13. Driessen M., Kienhuis A.S., Pennings J.L.A., Pronk T.E., van de Brandhof E.-J., Roodbergen M., Spaink H.P., van de Water B., van der Ven L.T.M. Exploring the zebrafish embryo as an alternative model for the evaluation of liver toxicity by histopathology and expression profiling. Arch. Toxicol. 2013, 87:807-823.
14. Ellinger-Ziegelbauer H., Adler M., Amberg A., Brandenburg A., Callanan J.J., Connor S., Fountoulakis M., Gmuender H., Gruhler A., Hewitt P., Hodson M., Matheis K.A., McCarthy D., Raschke M., Riefke B., Schmitt C.S., Sieber M., Sposny A., Suter L., Sweatman B., Mally A. The enhanced value of combining conventional and omics analyses in early assessment of drug-induced hepatobiliary injury. Toxicol. Appl. Pharmacol. 2011, 252:97-111.
15. Goldstone J.V., McArthur A.G., Kubota A., Zanette J., Parente T., Jönsson M.E., Nelson D.R., Stegeman J.J. Identification and developmental expression of the full complement of cytochrome P450 genes in zebrafish. BMC Genomics 2010, 11:643.
16. Hermsen S.A.B., Pronk T.E., van den Brandhof E.-J., van der Ven L.T.M., Piersma A.H. Transcriptomic analysis in the developing zebrafish embryo after compound exposure: individual gene expression and pathway regulation. Toxicol. Appl. Pharmacol. 2013, 272:161-171.
17. Hill A., Mesens N., Steemans M., Xu J.J., Aleo M.D. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab. Rev. 2012, 44:127-140.
18. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31:e15.
19. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of Hepatotoxicity. Toxicol. Sci. 2002, 65:166-176.
20. Jaeschke H., Knight T.R., Bajt M.L. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol. Lett. 2003, 144:279-288.
21. Jaeschke H., McGill M.R., Ramachandran A. Oxidant stress mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev. 2012, 44:88-106.
22. Jones M., Ball J.S., Dodd A., Hill A.J. Comparison between zebrafish and Hep G2 assays for the predictive identification of hepatotoxins. Toxicology 2009, 262:13-14.
23. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003, 349:474-485.
24. Leitner J.M., Graninger W., Thalhammer F. Hepatotoxicity of antibacterials: pathomechanisms and clinical. Infection 2010, 38:3-11.
25. NCBI Resource Coordinators Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2014, 42:D7-17.
26. Nciri R., Allagui M.S., Bourogaa E., Saoudi M., Murat J.-C., Croute F., Elfeki A. Lipid peroxidation, antioxidant activities and stress protein (HSP72/73, GRP94) expression in kidney and liver of rats under lithium treatment. J. Physiol. Biochem. 2012, 68:11-18.
27. Peterson R.T., Macrae C.A. Systematic approaches to toxicology in the zebrafish. Annu. Rev. Pharmacol. Toxicol. 2012, 52:433-453.
28. Santangeli P., Di Biase L., Burkhardt J.D., Bai R., Mohanty P., Pump A., Natale A. Examining the safety of amiodarone. Expert Opin. Drug Saf. 2012, 11:191-214.
29. Serviddio G., Bellanti F., Giudetti A.M., Gnoni G.V., Capitanio N., Tamborra R., Romano A.D., Quinto M., Blonda M., Vendemiale G., Altomare E. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic. Biol. Med. 2011, 51:2234-2242.
30. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
31. Silva M.F., Aires C.C., Luis P.B., Ruiter J.P., IJ L., Duran M., Wanders R.J., Tavares de Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 2008, 31:205-216.
32. Sukardi H., Chng H.T., Chan E.C.Y., Gong Z., Lam S.H. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Expert Opin. Drug Metab. Toxicol. 2011, 7:579-589.
33. Tsukamoto M., Tampo Y., Sawada M., Yonaha M. Paraquat-induced oxidative stress and dysfunction of the glutathione redox cycle in pulmonary microvascular endothelial cells. Toxicol. Appl. Pharmacol. 2002, 178:82-92.
34. Vitins, A.P., Kienhuis, A.S., Speksnijder, E.N., Roodbergen, M., Ven der, L.T.M.V. A mouse in vivo study of liver necrosis inducing chemical compounds acetaminophen, paraquat, and isoniazid identifies robust markers for the onset and progression of disease (in preparation).
35. Wagner M., Zollner G., Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 2009, 51:565-580.
36. Yamamoto Y., Moore R., Hess H.A., Guo G.L., Gonzalez F.J., Korach K.S., Maronpot R.R., Negishi M. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J. Biol. Chem. 2006, 281:16625-16631.
37. Zidek N., Hellmann J., Kramer P.-J., Hewitt P.G. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol. Sci. 2007, 99:289-302.
38. Zimmerman H.J., 1999. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver.